Titre : Interleukine-27

Interleukine-27 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement System Proteins
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interleukine-27 : Questions médicales les plus fréquentes", "headline": "Interleukine-27 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interleukine-27 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interleukine-27" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Interleukines", "url": "https://questionsmedicales.fr/mesh/D007378", "about": { "@type": "MedicalCondition", "name": "Interleukines", "code": { "@type": "MedicalCode", "code": "D007378", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.465" } } }, "about": { "@type": "MedicalCondition", "name": "Interleukine-27", "alternateName": "Interleukin-27", "code": { "@type": "MedicalCode", "code": "D064094", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Cory M Robinson", "url": "https://questionsmedicales.fr/author/Cory%20M%20Robinson", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Tomozumi Imamichi", "url": "https://questionsmedicales.fr/author/Tomozumi%20Imamichi", "affiliation": { "@type": "Organization", "name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA." } }, { "@type": "Person", "name": "Jessica M Povroznik", "url": "https://questionsmedicales.fr/author/Jessica%20M%20Povroznik", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Jordan K Vance", "url": "https://questionsmedicales.fr/author/Jordan%20K%20Vance", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Xiaojun Hu", "url": "https://questionsmedicales.fr/author/Xiaojun%20Hu", "affiliation": { "@type": "Organization", "name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis.", "datePublished": "2023-04-11", "url": "https://questionsmedicales.fr/article/37065697", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.15125" } }, { "@type": "ScholarlyArticle", "name": "Relationship between the complement system and serum lipid profile in patients with rheumatoid arthritis.", "datePublished": "2024-07-12", "url": "https://questionsmedicales.fr/article/39072319", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1420292" } }, { "@type": "ScholarlyArticle", "name": "The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis.", "datePublished": "2024-07-08", "url": "https://questionsmedicales.fr/article/38978073", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13075-024-03360-3" } }, { "@type": "ScholarlyArticle", "name": "The Contribution of Complement Protein C1q in COVID-19 and HIV Infection Comorbid with Preeclampsia: A Review.", "datePublished": "2022-06-03", "url": "https://questionsmedicales.fr/article/35661665", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000524976" } }, { "@type": "ScholarlyArticle", "name": "Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism.", "datePublished": "2023-06-07", "url": "https://questionsmedicales.fr/article/37286573", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-023-38383-y" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Interleukines", "item": "https://questionsmedicales.fr/mesh/D007378" }, { "@type": "ListItem", "position": 6, "name": "Interleukine-27", "item": "https://questionsmedicales.fr/mesh/D064094" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interleukine-27 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interleukine-27", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interleukine-27", "description": "Comment mesurer l'IL-27 dans le sang ?\nQuels tests sont utilisés pour évaluer l'IL-27 ?\nL'IL-27 est-elle mesurée dans des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-27 ?\nL'IL-27 peut-elle être un indicateur de gravité ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+System+Proteins&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interleukine-27", "description": "Quels symptômes sont liés à une élévation de l'IL-27 ?\nL'IL-27 est-elle liée à des douleurs articulaires ?\nQuels signes cliniques sont associés à l'IL-27 ?\nL'IL-27 influence-t-elle les symptômes respiratoires ?\nY a-t-il des symptômes neurologiques liés à l'IL-27 ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+System+Proteins&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Interleukine-27", "description": "Peut-on prévenir l'élévation de l'IL-27 ?\nY a-t-il des vaccins liés à l'IL-27 ?\nComment l'alimentation influence-t-elle l'IL-27 ?\nL'exercice physique affecte-t-il l'IL-27 ?\nLe sommeil influence-t-il l'IL-27 ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+System+Proteins&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interleukine-27", "description": "Quels traitements ciblent l'IL-27 ?\nL'IL-27 peut-elle être inhibée ?\nQuels médicaments affectent l'IL-27 ?\nL'IL-27 est-elle une cible pour l'immunothérapie ?\nComment l'IL-27 influence-t-elle les traitements ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+System+Proteins&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interleukine-27", "description": "Quelles complications sont liées à l'IL-27 ?\nL'IL-27 est-elle impliquée dans des maladies chroniques ?\nComment l'IL-27 affecte-t-elle le cancer ?\nY a-t-il des risques d'infection liés à l'IL-27 ?\nL'IL-27 est-elle liée à des troubles neurologiques ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+System+Proteins&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interleukine-27", "description": "Quels facteurs augmentent l'IL-27 ?\nL'âge influence-t-il les niveaux d'IL-27 ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe tabagisme affecte-t-il l'IL-27 ?\nY a-t-il un lien entre l'IL-27 et l'alimentation ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+System+Proteins&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer l'IL-27 dans le sang ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut être mesurée par des tests ELISA dans des échantillons de sérum." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'IL-27 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests immunologiques comme l'ELISA et la cytométrie en flux sont utilisés." } }, { "@type": "Question", "name": "L'IL-27 est-elle mesurée dans des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est souvent mesurée dans des maladies auto-immunes et inflammatoires." } }, { "@type": "Question", "name": "Quels biomarqueurs sont associés à l'IL-27 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 est souvent associée à d'autres cytokines comme l'IL-6 et l'IL-10." } }, { "@type": "Question", "name": "L'IL-27 peut-elle être un indicateur de gravité ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés d'IL-27 peuvent indiquer une inflammation sévère." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une élévation de l'IL-27 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une élévation de l'IL-27 peut entraîner des symptômes d'inflammation comme la fièvre." } }, { "@type": "Question", "name": "L'IL-27 est-elle liée à des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 peut contribuer à des douleurs articulaires dans les maladies inflammatoires." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à l'IL-27 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes cliniques incluent fatigue, douleurs et symptômes systémiques d'inflammation." } }, { "@type": "Question", "name": "L'IL-27 influence-t-elle les symptômes respiratoires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 peut exacerber les symptômes respiratoires dans certaines maladies pulmonaires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à l'IL-27 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent être associés à des symptômes neurologiques dans certaines conditions." } }, { "@type": "Question", "name": "Peut-on prévenir l'élévation de l'IL-27 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des modes de vie sains et une gestion du stress peuvent aider à prévenir l'élévation de l'IL-27." } }, { "@type": "Question", "name": "Y a-t-il des vaccins liés à l'IL-27 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant l'IL-27." } }, { "@type": "Question", "name": "Comment l'alimentation influence-t-elle l'IL-27 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation anti-inflammatoire peut aider à réguler les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'exercice physique affecte-t-il l'IL-27 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire les niveaux d'IL-27 et améliorer la santé immunitaire." } }, { "@type": "Question", "name": "Le sommeil influence-t-il l'IL-27 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un sommeil adéquat est crucial pour maintenir des niveaux sains d'IL-27 et une bonne santé." } }, { "@type": "Question", "name": "Quels traitements ciblent l'IL-27 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies biologiques ciblant l'IL-27 sont en développement pour les maladies auto-immunes." } }, { "@type": "Question", "name": "L'IL-27 peut-elle être inhibée ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des inhibiteurs spécifiques de l'IL-27 sont à l'étude pour réduire l'inflammation." } }, { "@type": "Question", "name": "Quels médicaments affectent l'IL-27 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments anti-inflammatoires peuvent moduler les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'IL-27 est-elle une cible pour l'immunothérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est une cible potentielle pour l'immunothérapie dans le cancer." } }, { "@type": "Question", "name": "Comment l'IL-27 influence-t-elle les traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut influencer l'efficacité des traitements en modulant la réponse immunitaire." } }, { "@type": "Question", "name": "Quelles complications sont liées à l'IL-27 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent entraîner des complications dans les maladies auto-immunes." } }, { "@type": "Question", "name": "L'IL-27 est-elle impliquée dans des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est associée à des maladies chroniques comme l'arthrite et le lupus." } }, { "@type": "Question", "name": "Comment l'IL-27 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut avoir un rôle double dans le cancer, favorisant ou inhibant la croissance tumorale." } }, { "@type": "Question", "name": "Y a-t-il des risques d'infection liés à l'IL-27 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent augmenter le risque d'infections en modulant l'immunité." } }, { "@type": "Question", "name": "L'IL-27 est-elle liée à des troubles neurologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux d'IL-27 peuvent être associés à des troubles neurologiques comme la sclérose en plaques." } }, { "@type": "Question", "name": "Quels facteurs augmentent l'IL-27 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, l'obésité et les infections chroniques peuvent augmenter les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'IL-27 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux d'IL-27 peuvent augmenter avec l'âge, affectant la réponse immunitaire." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes atteintes de maladies auto-immunes présentent souvent des niveaux élevés d'IL-27." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il l'IL-27 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux d'IL-27 et aggraver l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il un lien entre l'IL-27 et l'alimentation ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires peuvent influencer les niveaux d'IL-27, notamment les régimes riches en sucres." } } ] } ] }

Sources (10000 au total)

Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis.

IgA nephropathy (IgAN) is one of the leading causes of end-stage renal disease (ESRD). Urine testing is a non-invasive way to track the biomarkers used for measuring renal injury. This study aimed to ... In the discovery phase, we analysed 22 IgAN patients who were divided into three groups (IgAN 1-3) according to their estimated glomerular filtration rate (eGFR). Eight patients with primary membranou... In the discovery phase, 747 proteins were identified in the urine of IgAN and pMN patients. There were different urine protein profiles in IgAN and pMN patients, and the bioinformatics analysis reveal... There were abundant complement components in the urine of IgAN patients, indicating that the activation of AP and LP is involved in IgAN progression. Urinary complement proteins may be used as biomark...

Relationship between the complement system and serum lipid profile in patients with rheumatoid arthritis.

The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which has been attributed to the inflamm... 430 patients with RA were recruited. New-generation techniques were employed to conduct functional assays of the three pathways of the complement system. Serum levels of various complement components ... After multivariable analysis, several noteworthy associations emerged between the complement system and lipid molecules. Notably, complement components most strongly linked to the lipid profile were C... The correlation between the complement system and lipid molecule patterns is pronounced in patients with RA. This relationship is predominantly positive and primarily associated with upstream compleme...

The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis.

Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Subclinical carotid atherosclerosis is independently associated with rates of incident CV... 430 patients with RA were recruited. Functional assays of the three pathways of the complement system, utilizing new-generation techniques, were assessed. Additionally, serum levels of individual comp... After multivariable adjustment, which included traditional CV risk factors and disease-related data, C3a and C5a exhibited significant positive correlations with carotid intima media thickness. Additi... The complement system and subclinical carotid atherosclerosis are linked in patients with RA....

The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target.

The purpose of this review is to discuss the role of the complement system in the pathogenesis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) as well as the employment of co... AAV has traditionally been considered a pauci-immune disease until recent findings demonstrated the pathogenic role of the complement system. The complement alternative pathway is crucial in AAV, and ... The increased circulating levels of some complement components - as well as the consumption of others - in patients with AAV suggested a systemic activation of the complement system. Low C3 levels cor...

Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study.

Neuroinflammation is emerging as an important pathological process in frontotemporal dementia (FTD), but biomarkers are lacking. We aimed to determine the value of complement proteins, which are key c... We measured the complement proteins C1q and C3b in CSF by ELISAs in 224 presymptomatic and symptomatic GRN, C9orf72 or MAPT mutation carriers and non-carriers participating in the Genetic Frontotempor... CSF C1q and C3b, as well as plasma C2 and C3, were elevated in symptomatic mutation carriers compared to presymptomatic carriers and non-carriers. In genetic subgroup analyses, these differences remai... Elevated levels of CSF C1q and C3b, as well as plasma C2 and C3, demonstrate the presence of complement activation in the symptomatic stage of genetic FTD. Intriguingly, correlations with several dise...